Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab for peanut allergy
2020-005339-56Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ligelizumab in peanut allergy (3 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Oct 2021; status: terminated.
02
Drugs
ligelizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2020-005339-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005339-56.